Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis.

What It Covers

The paper reports a study of Abaloparatide and Teriparatide, published as a systematic review.

The researchers performed pairwise meta-analysis using Stata 18.0 software to assess the magnitude of effect sizes and the consistency of findings across studies.

Why It Was Studied

Currently, a variety of medications are available for the treatment of male osteoporosis, including abaloparatide, denosumab, teriparatide, and bisphosphonates.

However, there is a lack of sufficient systematic comparative studies to guide the choice between these treatments, particularly for specific male osteoporosis populations.

Who the Included Studies Covered

PubMed tags the participants as men only.

This systematic review and network meta-analysis (NMA) were conducted strictly in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and the relevant standards recommended by the Cochrane Collaboration.

For network meta-analysis (NMA), the researchers used R version 4.3.1 along with the gemtc and BUGSnet packages to handle complex multi-treatment comparisons.

How the Review Was Done

A Systematic Review and Bayesian Network Meta-Analysis.

All statistical analyses were conducted using Review Manager software (version 5.4), a widely used tool in medical research for meta-analysis, forest plot generation, and bias risk assessment.

What Was Measured

Topics PubMed links to this paper include Administration, Intravenous, Bayes Theorem, Bone Density Conservation Agents, Denosumab, Diphosphonates, Osteoporosis and Parathyroid Hormone-Related Protein.

Author keywords: abaloparatide, bisphosphonates, male osteoporosis and teriparatide.

What This Means in Plain Language

This is a systematic review of Abaloparatide and Teriparatide.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Abaloparatide compound page and the Teriparatide compound page, all human trials.